Centerline Biomedical

Executive Summary

Centerline Biomedical is a Cleveland-based private medical device company developing innovative navigation technology for cardiovascular procedures. Founded in 2014, the company aims to reduce radiation exposure and improve procedural accuracy for both patients and caregivers. Its platform addresses a critical need in interventional cardiology and vascular surgery, where traditional fluoroscopy-based navigation poses radiation risks and limited precision. By offering real-time, radiation-free guidance, Centerline's technology has the potential to enhance patient safety and clinical outcomes while reducing occupational hazards for healthcare providers. Although specific funding, valuation, and revenue details are not disclosed, the company operates in a growing market driven by increasing adoption of minimally invasive procedures and demand for safer navigation alternatives. The regulatory pathway and commercial traction remain unclear, but the technology's value proposition aligns with key industry trends toward dose reduction and precision medicine.

Upcoming Catalysts (preview)

• Q2 2027FDA 510(k) Clearance or CE Mark for Lead Product60% success
• Q4 2026Strategic Partnership or Distribution Agreement with Major Cardiovascular Device Company50% success
• Q1 2027Publication of Pivotal Clinical Study Results Demonstrating Superiority Over Standard Navigation55% success